Clifford Chance advises on TenNor Therapeutics' IPO and listing in Hong Kong
22 May 2026
Clifford Chance advises on TenNor Therapeutics' IPO and listing in Hong Kong
Global law firm Clifford Chance has advised the joint sponsors CITIC Securities (Hong Kong) Limited and ABCI Securities Company Limited on the initial public offering and listing of TenNor Therapeutics (Suzhou) Limited on the Main Board of the Hong Kong Stock Exchange, under the Exchange's Chapter 18A Listing Rules for Biotech Companies.
Founded in 2013 in Suzhou, TenNor Therapeutics is a biotechnology company which focuses on developing differentiated treatments for bacterial infections and metabolic diseases to combat antimicrobial resistance, a global health threat.
Partners Fang Liu, Virginia Lee and partner of Clifford Chance (Beijing) Claire Cao co-led the transaction with support from counsel Haoze Zheng, senior associate Astrid Zhuang, associates Cathy Qian and Ke Shi, trainee solicitors Zhongxiao Cong and Ruiyi Chen, legal analysts Bofan Xu, Andy Jiang, Vanessa Xu, paralegal Jay Lee.
Clifford Chance is a leading adviser of pharmaceutical, biotech and healthcare companies, having advised most recently on the listings of Star Sports Medicine, Edge Medical and Lepu Biopharma.
Press contact: Fenix Wong
高伟绅为丹诺医药在香港首次公开发行及18A章上市提供法律服务
国际领先律师事务所高伟绅就丹诺医药（苏州）股份有限公司（“丹诺医药”）通过《上市规则》第18A章（适用于生物科技公司），在香港交易所主板完成首次公开发行及上市，担任联席保荐人中信证券（香港）有限公司和农银国际融资有限公司的国际法律顾问。
丹诺医药于2013年在苏州创立，是一家专注研发细菌感染与代谢疾病差异化疗法，以应对抗菌药物耐药性这一全球健康威胁的生物科技公司。
本交易由合伙人方刘、李婉雯和曹阳共同牵头，团队成员包括郑镐泽、庄立平、钱超、石可、丛中笑、陈睿怡、徐博帆、姜栢安和徐咏晴。
高伟绅在医药、生物科技及医疗健康行业具备领先经验，近期已为天星医疗、精锋医疗及乐普生物等企业的香港上市项目提供专业法律服务。
